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The effects of intracerebroventricularly (i.c.v.) administered
synthetic somatostatins (SRIH-14 and SRIH-28) on pituitary TSH cells
of adult female rats were studied. Theanimals were i.c.v. injected with
three 1.0Jig (5 Jil) doses of SRIH-14or SRIH-28every second day and
sacrificed five days after the last dose. The controls received an
equivalent volume ofsaline in the same manner according to the same
schedule. The pituitary glands were excised and used for
immunohistochemical and morphometric evaluation. The results
obtained demonstrated a somatostatin-related decrease in relative
pituitary weight. The morphometric analyses showed decreased
volumetric density of TSH-immunoreactive cells in SRIH-treated
groups, but this difference was more expressed in SRIH-14- treated
animals than in those receiving SRIH-28. On the basis of these results
it can be concluded that centrally administered somatostatins inhibit
TSH cells.
Key words: female rats, pituitary, TSH cells, immuno-
histochemistry, somatostatin
INTRODUCTION
Somatostatin (SRIH) is synthesized as a prohormone which undergoes
tissue-specific processing resulting in either a 14 amino acid peptide (SRIH -14)
or a 28 amino acid, N-terminally extended form (SRIH-28) which are present in
the hypothalamus in the ratio of 4:1 (Gillies, 1997). SRIH is widely distributed in
higher organisms and expresses inhibitory effects on the secretion of various
polypeptide hormones. Epelbaum et al. (1987) suggested that SRIH-14 was 8
times more potent than SRIH-28 with regard to TSH secretion. Five specific
subtypes of somatostatin receptors have been cloned, each of them having a
characteristic tissue-specific pattern of expression (Coy and Rossowski, 1995).
They have been described and characterized in rat pituitary gland, the central
nervous system, adrenal cortex and pancreatic acini (Aguilera and Parker, 1982;
Srikant and Patel, 1985). In the adenohypophysis SRIH-binding sites were iden-
tified on the three target cell types: somatotrophs, thyrotrophs and lactotrophs
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(Epelbaum et aI., 1987; Day et aI., 1995). Originally, somatostatin was shown to
inhibit growth hormone (GH) secretion as a neuroendocrine hormone (Milosevic
et aI., 1998). However, it is less well known, but nonetheless important, that SRIH
plays a physiological role in the regulation of the hypothalamo-pituitary-thyroid
axis (Singer, 1990). It has been reported that TSH secretion is stimulated by TRH,
while somatostatin inhibits TSH synthesis and release (Theodoropoulos, 1985).
SRIH inhibition of TRH-stimulated TSH secretion has been demonstrated in
neonatal 3 day old rats, but no effect on basal TSH levels was observed during
the first 60 days of life (Oliver et aI., 1982). The inhibitory action of somatostatin
was confirmed by discrete lesions of SRIH neurons in the rat periventricular
nucleus of the preoptic-anterior hypothalamus leading to transient elevation in GH
and TSH secretion (Critchlow et. al., 1981).
Huffman et al. (1990) suggested that somatostatin did not affect thyroid
hormone or plasma calcium levels, while plasma TSH was decreased in rats.
Recent data of Roussel et al. (1997) showed that SRIH inhibits TSH response to
physiological concentrations of TRH in primary cultures of rat anterior pituitary
cells in a dose-dependent manner. Similarly increased hypothalamic SRIH levels
induced by oral glucose administration were found to suppress TRH-stimulated
TSH response in man (Yang et aI., 1996).
James et al. (1997) showed a synergistical action of thyroid hormone (T4)
and somatostatin to control TSH secretion, expressing both anti-secretory and
anti-proliferative effects on pituitary thyrotroph tumours in mice. Somatostatin
decreased pituitary TSH secretion, caused tumour shrinkage when used for
treatment of human pituitary thyrotropinomas (Comi et aI., 1987) and also sup-
pressed proliferation of a human differentiated thyroid carcinoma cell line (Ain et
al.,1997).
All these data prompted us to examine possible effects of i.c.v. applied
SRIH-14 or SRIH-28 on morphometric characteristics of pituitary TSH cells in adult
rat females.
MATERIAL AND METHODS
Adult two-month-old female Wistar rats were used. They were kept under a
12/12 h light-dark cycle at 22±2 C, and fed commercial rat chow.
Surgical procedures were performed under ether anaesthesia. A headset
was implanted into the rats and used later for intracerebroventricular (i.c.v.)
injections. The headset consisted of a Silastic-sealed 20-gauge cannula (Starcevtc
et al., 1988), implanted into a lateral cerebral ventricle, 1.0 mm posterior and 1.5
mm lateral to the bregma and 3 mm below the cortical surface. A small stainless
steel anchor screw was placed at a remote site on the skull. The cerebroventricular
cannula and screw were cemented to the skull with dental acrylic resin (Simgal;
ICN, Yugoslavia).
After recovery from the surgical procedure (5 days), the rats were divided
into three experimental groups, each consisting of 5 animals. Two groups were
given i.c.v. three 1.0 /1g doses of SRIH-14 or SRIH-28 (S 9129 and S 6135,
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respectively; Sigma, St. Louis, MO, USA) dissolved in 5 pi saline every second
day. All animals were sacrificed under deep ether anaesthesia by decapitation, 5
days after the last injection.
The pituitary glands were immediately excised, measured, fixed in Bouirrs
solution for 48 h and embedded in paraffin. Serial 4 urn thick sections were
mounted on gelatine-coated glass slides. TSH-producing cells were studied using
the peroxidase-antiperoxidase (PAP) method as already described (Sekulic et al.,
1995). TSH [3 immunoreactive cells in the pituitary pars distalis were stereologically
analyzed by simple point counting (Weibel, 1979). Morphometric parameters
(mean volumes of TSH cells and the nuclei and relative volume density of these
cells) were measured exactly as previously (Sekulic et aI., 1995).
The data obtained for each rat were averaged per group and the standard
error of the mean (SEM) was calculated. The the statistical significance of
differences between mean values was evaluated by using Student's t-test.
RESULTS
Body weight of somatostatin-treated rats decreased in comparison with the
values recorded at the onset of the experiment, but the difference was not
statistically significant. Relative pituitary weight of the rats treated with SRIH-14 or
SRIH-28 decreased by 9% and 5% respectively compared to the controls
(Table 1).
Table 1. Effects of intracerebroventricularly applied SRIH-14 or SRIH-28 on body and relative
pituitary weight in adult female rats
Experimental group
Control
SRIH-14
SRIH-28
Body weight (g)
238.0 ± 604
234.0± 4.0
220.0 ± 12.2
Relative pituitary weight
(mg%)
4.3 ± 0.1
3.9 ± 0.23
4.1 ±Oo4
The values are the mean SEM; n=5
TSH immunoreactive cells of control adult female rats were localized in the
anteromedial portion of the anterior pituitary gland. They had a round or irregular
shape with long cytoplasmic elongations, situated singly or in clusters, and were
strongly immunostained (Fig. 1a). The average TSH cell volume was 1113 pm3
(Fig. 2a) and they made up 10% of the pituitary volume (Fig. 2c).
TSH immunoreactive cells in SRIH-14-treated animals were small, often
pycnotic and darkly stained (Fig. 1b). A significant decrease of both cellular and
nuclear volume of TSH cells (24% and 23%, respectively) was observed (Figs. 2a
b).
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Figure 1. a. Immunoreactive TSH cells in pituitary pars distalis of a control adult rat female. b. Rarely
distributed small TSH cells in an SRIH-14-treated animal. (PAP; X 700).
Most vacuolated TSH cells were noticed in rats administered SRIH-28.Some
pycnotic cells were also seen and cytoplasmic elongations were seldom. Cell
volume and nuclear volume of TSH cells were unchanged (Fig. 2a).
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Figure 2. a. Cellular (Jvc ) volume (urn:') of the imrnunojeactive TSH cells b. Nuclear (Vvn ) volume
(pm3) of TSH cells; c. Relative volume density (Vv ) of cells expressed as percentages of total
gland tissue. C - control, SRIH-14 and SRIH-28- somatostatin-treated adult rat females. All
values are the means ± SEM, °p<O.025; **P<O.005; ***P<O.001.
8 Acta Veterinaria (Beograd), Vol. 50, No.1, 3-12, 2000.
Milka Sekulic et. al. Somatostatin acts by inhibiting pituitary TSH cells
in female rats
DISCUSSION
The results of the present study demonstrate that i.c.v. administered soma-
tostatin, at first isolated on the basis of its capacity to inhibit GH secretion (Reichlin,
1983), and especially SRIH -14, expressed inhibitory effects on TSH cell structure
as well as their volume in adult female rats.
It is generally accepted that somatostatin, a hypothalamic tetradecapeptide,
directly inhibits anterior pituitary secretion of TSH, and may also inhibit TRH
secretion. Based on its tonic inhibitory effect it was assumed that in perinatal rats
somatostatin represents a physiological regulator of TSH secretion operating
before TRH (Theodoropoulos, 1985). SRIH and dopamine, acting at the pituitary
level as neurohormones and neurotransmitters, can contribute to CNS modulation
of TSH release (Fisher and Polk, 1989). A modulatory role for SRIH in TSH control
of adult rats was suggested by Oliver et al. (1982) who found that the
administration of SRIH antiserum increased basal TSH level and potentiated TSH
response to cold. Recent data of Roussel et al. (1997) showed that SRIH inhibited
TSH response to TRH in a dose-dependent manner, but the mechanism(s)
underlying this effect is still unclear. Crichlow et al. (1981) confirmed the inhibitory
role of SRIH in controlling TSH secretion, since discrete lesions in the
periventricular zone of the anterior hypothalamus caused transient elevation in
GH and TSH secretion.
Biological actions of SRIH-14 are receptor -mediated, and besides the CNS,
SRIH-14-specific receptors have been characterised in the pituitary (Srikant and
Patel, 1985). Coy and Rossowski (1995) suggested the presence of several
subtypes of somatostatin receptors and successfully cloned five of them.
TSH cells are a target for SRIH and, for that reason, the aim of our study was
to examine the effects of low doses of i.c.v. injected SRIH-14 or SRIH-28 on
immunoreactive TSH cells. Morphometric and quantitative changes in TSH
pituitary cells were more obvious in SRIH-14- than in SRIH -28-treated animals. A
significant decrease of TSH cells volume by 24% was observed in the
SRIH-14-treated group, while after SRIH -28 this parameter was decreased by 7%
only, in comparison with the controls. Cytological features of immunoreactive TSH
cells in the SRIH-14-treated group indicate clear signs of inhibitory changes, seen
as pycnotic involutive cells. Our results revealed less inhibition of TSH cells after
SRIH-28 and additional examinations are necessary to explain the action of this
hormone. The differences in morphometric parameters of TSH immunoreactive
cells between SRIH-14- and SRIH-28-treated animals, could be explained in terms
of the 8 times higher potency of SRIH - 14 as an inhibitor of TSH secretion, as
suggested by Epelbaum et al. (1987).
The decrease of relative pituitary weight in somatostatin-treated female rats
observed in our study corresponded well with decreased body weight but these
differences were not statistically significant, probably due to the short period of
treatment, i.e. the time from the onset to the end of the experiment.
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It has been demonstrated that the effect of SRIH on the secretion of GH, PRL
and TSH from anterior pituitary of female rats is mediated through the activation
of a single class of membrane receptors (Epelbaum et al. 1987). However, the
inhibition of hormone secretion by SRIH cannot be explained solely by adenylate
cyclase inhibition, and some other mechanism(s) could operate. Roussel et al.
(1997) suggested that SRIH attenuates Ca2+ influx into rat pituitary cells thus
reducing TSH secretion in primary cell cultures.
The potential use of SRIH analogues in the treatment of clinical conditions
ranging from human cancers to Alzheimer's and Parkinson's diseases is of great
interest. DeRosa et al. (1983) found that somatostatin significantly reduced the
TSH response to TRH in normal or hypothyroid subjects and in patients with TSH
secreting pituitary adenoma, while it did not influence basal TSH level in normal
or hypothyroid subjects. These results indicate a potential therapeutic use of
somatostatins in thyroid diseases. SRIH and its analogues have been shown to
inhibit the proliferation of human thyroid carcinoma cell lines, as well (Ain et aI.,
1997).
Somatostatin-binding sites on the cell surface of the thyrotropic tumour cells
and thyroid hormones playa pivotal role in regulating somatostatin receptors in
murine thyrotrope tumours. Thyroid hormones influence the somatostatinergic
system and control antisecretory and antiproliferative somatostatin effects in
thyrotropic cells. In fact, thyroid hormones and somatostatin act synergistically to
control TSH secretion (James et al. 1997).
It is well established that SRIH acts on somatotrophs in the anterior pituitary
gland via its G protein-coupled, transmembrane receptor domain to reduce cAMP
formation and to inhibit the secretion but not the synthesis of GH (Gillies, 1997).
It is possible that the same mechanism of SRIH action on TSH is operational and
that its inhibitory effects are directly expressed at the level of the thyrotrophs.
In summary, our results indicate that centrally administered SRIHs inhibit
TSH cell structure. Additional studies will be necessary to explain the mechanism
of their action on thyrotropic function.
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INHIBITORNO DELOVANJE SOMATOSTATINA NA TSH CELIJE HIPOFIZE U ZENKI PACOVA
MILKA SEKULlC, MIRJANA LOVREN i VERICA MILOSEVIC
SADRZAJ
Ispitivani su efekti intraeerebroventrikularno (i.c.v.) injieiranih sintetickih
somatostatina (SRIH-14 i SRIH-28) na hipofizne TSH celi]e adultnih zenki paeova.
Zivotirqe su i.e.v. injieirane sa tri doze od po 1 llg SRIH-14 iii -28 rastvorenog u 5
III fizioloskoq rastvora svaki drugi dan, a zrtvovane 5 dana posle poslednje
injekcije. Kontrole su tretirane odqovarajucorn dozom fizioloskoq rastvora.
Hipofize su izolovane i pripremljene za imunocitohemijska i morfometrijska isplti-
vanja. Oba somatostatina izazivaju smanjenje relativne tezine hipofize. Morfo-
metrijska analiza pokazuje da je u obe tretirane grupe zlvotlnja volumenska
gustina TSH-imunoreaktivnih celija smanjena ate razlike su znacajni]e izrazene u
grupi zivotinja tretiranih sa SRIH-14 u odnosu na one tretirane sa SRIH-28. Na
osnovu dobijenih rezultata mozerno zakljuciti da eentralno aplikovani sornatostat-
ini inhibiraju TSH celije hipofize.
